Date: 2018-09-10
Type of information: Restructuring
Compound:
Company: Glythera, now Iksuda Therapeutics (UK)
Therapeutic area: Cancer - Oncology
Type agreement: restructuring - corporate name change
Action mechanism:
Disease:
Details:
- • On September 10, 2018, Glythera, a next-generation Antibody Drug Conjugate (ADC) development company, announced that it has changed its name to Iksuda Therapeutics (Iksuda) and unveiled a new corporate brand. The new identity signifies the company's transition from technology licensing to drug development, focusing on cancer therapeutics and the treatment of solid tumours. To coincide with the rebranding, Iksuda Therapeutics has launched a new website: www.iksuda.com.
- Iksuda's primary focus will be on the development of superior ADCs for treatment of difficult-to-treat cancers, but the Company will continue to support its partners' portfolios with its advanced conjugation platform, PermaLink®, and novel toxin payloads.
- Iksuda anticipates that it will nominate two ADCs for clinical progression in Q4 2018, with first indications expected to be ovarian and lung cancers. To support its pre-clinical and clinical activities, the Company has significantly expanded its team over the past 12 months, including the appointment of Dr Robert Lutz's as CSO in January 2018.
Financial terms:
Latest news:
Is general: Yes
